Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.41 |
| ▸ | JAK2 | O60674 | 4/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909020 | 0.83 | ADORA3 (0.48) | BRD4JAK2PTK2PIK3CDPIK3CA | |
| SCHEMBL4916898 | 0.83 | ADORA3 (0.45) | BRD4JAK2PTK2PDE5APIK3CD | |
| SCHEMBL4916405 | 0.83 | JAK2 (0.41) | BRD4JAK2JAK3PTK2JAK1 | |
| SCHEMBL4937118 | 0.83 | JAK2 (0.41) | BRD4JAK2JAK3PTK2JAK1 | |
| SCHEMBL4937142 | 0.83 | JAK2 (0.41) | BRD4JAK2JAK3PTK2JAK1 | |
| SCHEMBL4917380 | 0.80 | PIK3CD (0.38) | BRD4JAK2JAK3PTK2JAK1 | |
| SCHEMBL4914661 | 0.77 | PTK2 (0.43) | BRD4JAK2JAK3PTK2JAK1 | |
| SCHEMBL4917631 | 0.76 | PTK2 (0.47) | BRD4JAK2JAK3PTK2PIK3CD | |
| SCHEMBL4909631 | 0.76 | PTK2 (0.41) | BRD4JAK2JAK3PTK2JAK1 | |
| SCHEMBL4916387 | 0.76 | PTK2 (0.41) | BRD4JAK2JAK3PTK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | GRK4, JAK2, ALK | BRD4 93/4885JAK2 2/4885JAK3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.